Piper Sandler analyst Allison Bratzel maintained a Buy rating on Akebia Therapeutics (AKBA – Research Report) today and set a price ...

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people ...

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people ...

英为财情Investing.com - Akebia Therapeutics (NASDAQ: AKBA)星期四发布了第三季度的财报，数据显示，公司营收逊于分析师的预期，每股收益低于分析师的预期。 在该公司发布的最新财报中，公司每股收益为$-0.100，总营收为$37.43M，而此前英为财情Investing.com对分析师的调查显示，分析师预期该公司的营收为$44.5M，每股收益为$-0.06 ...

Akebia (NASDAQ:AKBA) is scheduled to announce Q3 earnings results on Thursday, November 7th, before market open. The ...

Akebia Therapeutics ( (AKBA) ) has released its Q3 earnings. Here is a breakdown of the information Akebia Therapeutics presented to its ...

BTIG Research has recently resumed Akebia Therapeutics Inc (AKBA) stock to Buy rating, as announced on November 29, 2023, according to Finviz. Earlier, on August 28, 2023, H.C. Wainwright had raised ...

BTIG Research has recently resumed Akebia Therapeutics Inc (AKBA) stock to Buy rating, as announced on November 29, 2023, according to Finviz. Earlier, on August 28, 2023, H.C. Wainwright had raised ...

CAMBRIDGE, Mass., Nov. 7, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease ...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Akebia Therapeutics Inc. (AKBA) on Thursday reported a loss of $20 million in its third quarter. The Cambridge, Massachusetts-based company said it had ...